Dec 14 2009
Alcon (NYSE:ACL) announced today that it has entered into a definitive agreement to acquire Optonol, Ltd., a medical device company that develops, manufactures and markets novel miniature surgical implants used to lower intraocular pressure (IOP) in patients with glaucoma. With this acquisition, Alcon will acquire Optonol’s Ex-PRESS™ Mini Glaucoma Shunt. This agreement will complement Alcon’s pharmaceutical products that lower IOP in patients with glaucoma and ocular hypertension, and will be additive to the company’s growth opportunities.
“This transaction demonstrates Alcon’s strong commitment to providing physicians with comprehensive treatment options for patients with glaucoma, the world’s second leading cause of blindness,” said Robert Warner, Alcon’s vice president of U.S. pharmaceutical products. “This surgical procedure provides incremental surgeon and patient benefits over trabeculectomy, which is currently considered the standard of care in glaucoma surgical therapy.”
The American Medical Association (AMA) assigned the Ex-PRESS™ Mini Glaucoma Shunt to CPT® 0192T effective July 1, 2008 and it is currently reimbursed by Medicare and other payors. The device is also approved and currently marketed in Europe, Canada, Australia and several other countries.
“The acquisition of Optonol is part of our strategy to bolster organic growth with targeted investments in key therapeutic areas that have the potential to contribute in both the near and long term,” said Kevin Buehler, Alcon’s president and chief executive officer. “Because the product is already approved in the United States and other major markets it will begin contributing commercially in 2010.”
The closing of the acquisition is subject to customary closing conditions and the receipt of required regulatory approvals and is expected to occur by the end of the first quarter of 2010.
Source: Alcon, Inc.
Healthy lifestyle choices can offset genetic risk for brain diseases